

REMARKS

Claims 54-131 are pending in the application as amended. Claims 1-53 have been canceled without prejudice, and claims 54-131 have been added, in order to more particularly point out and distinctly claim that which Applicants regard as the invention. The new claims are fully supported by the specification and the claims as filed; the relationship of the presently pending claims to the claims as filed is set forth below in reference to the Requirement for Restriction.

In particular, the following sets out exemplary support for new claims 54-131. Additional support for the claims may be found elsewhere in the specification as filed.

Support for claim 54 is found on page 165 (claim 2) of the specification as filed.

Support for claim 55 is found on page 165 (claim 3), page 5, lines 15-24, and elsewhere in the specification.

Support for claim 56 is found on pages 105, 167 (claim 21), and elsewhere in the specification as filed.

Support for claim 57 is found on pages 105 and claim 22 of the specification as filed.

Support for claim 58 is found in part on page 168-169 (claim 26), Figure 4, pages 32-33 and elsewhere in the specification as filed.

Support for claim 59 is found in Figure 4 and pages 32-33 in the specification as filed.

Support for claim 60 is found on page 32, lines 26-29; page 33, lines 7-9; and elsewhere in the specification.

Support for claim 61 is found in claim 26, pages 32-33 and Figure 4 of the specification as filed.

Support for claim 62 is found in Figure 4 of the specification as filed.

Support for claim 63 is found on page 34, line 20 through page 35, line 17 of the specification as filed.

Support for claim 64-68 is found variously on pages 33, 103, 104, 123, lines 18-19, Figure 17, 21B, 21C, 22B and in claim 3 of the specification as filed.

Support for claim 69 is found on page 48 of the specification as filed.

Support for claims 70-74 is found on page 38, line 20 through page 42, line 6 and claims 23-25 of the specification as filed.

Support for claim 75 is found on pages 149 and 155.

Support for claim 76 is found on pages 149 and 155.

Support for claim 77 and 78, is found in claims 2-11, page 5 and the DNA sequences set out in the Figures of the specification as filed.

Support for claim 79 is found on pages 6, 26, 30, 40, and 47.

Support for claim 80 is found on pages 18, line 25; Figure 20; and Figure 21, lines 6-7.

Support for claims 81-84 is found on page 165 (claim 17 of the specification as filed) and the subject matter corresponds to the DIAS encoding the polypeptides set out in claims 64-67 set out above support for which is set out above.

Support for claim 85 is found on page 6, line 28 through page 7, line 2.

Support for claim 86 is found on page 6, lines 16-21 of the specification as follows.

Support for claim 87 is found on page 6, lines 16 through page 7, line 2 of the specification as filed.

Support for claim 88 is found on page 107 and claim 16 of the application as filed.

Support for claim 89 is found on pages 7; 43; 52, line 20 through 53; 103, line 8 through 105, line 6; pages 108-110, line 14; and claims 8 and 9 of the specification as filed.

Support for claim 90 is found on pages 52, line 26 through page 53, line 8 and page 103, line 8 through page 105, line 6 of the specification as filed.

Support for claim 91 and 92 is found on page 52 of the specification.

Support for claims 93-96 is found on page 7; page 53, lines 21-26; page 103, line 8 through page 105, line 6; and elsewhere in the specification as filed.

Support for claims 97-99 is found on page 50, lines 17-25 in the specification as filed.

Support for claim 100-103 is found on page 50, page 103, line 8 through page 105, line 6; page 108, line 1 to page 114, line 12; page 122, line 21 through page 124, line 12; page 150, line 27 to page 154, line 9; and page 155 line 1 through page 157 line 9.

Support for claim 104-108 is found on pages 59-65 of the specification as filed.

Support for claims 109-113 is found on pages 59-70 of the specification as filed.

Support for claims 114-117 is found on pages 75-83 and elsewhere in the specification as filed.

Support for claims 118-122 is found on pages 86-87 of the specification.

Support for claim 123 is found on page 49, lines 3-16; page 50, lines 5-8; and page 73, lines 9-14.

Support for claim 124 is found on pages 83-85 of the specification as filed.

Support for claim 125 is found on pages 72-83 of the specification as filed.

Support for claims 126 and 127 is found on pages 157-162 of the specification as filed.

Support for claim 128 is found on pages 73-85 of the specification as filed.

Support for claim 129 is found on page 172 (claim 52) of the specification as filed.

Support for claims 130 and 131 is found on pages 73-83 of the specification as filed.

Election Under 37 C.F.R. § 1.141

By this Office Action, the Examiner has required restriction to one of the following inventions under 35 U.S.C. § 121:

Group I. Claims 1-16 (new claims 77-79), drawn to isolated DNA, oligonucleotide, and transfected cells, classified in Class 536, subclass 23.1.

Group II. Claims 17-26 (new claims 54-76), drawn to polypeptides and polymers, classified in Class 530, subclass 399.

Group III. Claims 32-38 (new claims 104-107), drawn to antibodies and methods of preparing them, classified in Class 530, subclass 389.2.

Group IV. Claims 39-43 (new claims 109-113), drawn to methods of measuring ob polypeptide *in vitro*, classified in Class 435, subclass 7.1.

Group V. Claims 44-45 (new claims 122-123), drawn to methods of using antisense and ribozymes, classified in Class 514, subclass 44.


Group VI. Claims 46-49 (new claims 114-120, 125-127 and 130), drawn to pharmaceutical compositions of proteins and methods of using them, classified in Class 424, subclass 98.1.

Group VII. Claim 50 (new claim 124), drawn to gene therapy, classified in Class 514, subclass 44.

Group VIII. Claims 51-53 (new claims 116, 117, 128, 129 and 131, drawn to an ob antagonist, classified in various classes and subclasses depending on the molecule used.

In response, solely to be responsive to the requirement for restriction, Applicants elect to prosecute the invention of Group VII, Claims 124, drawn to a method for modifying body weight that utilizes gene therapy, with traversal.

Early and favorable action on the merits is courteously submitted.

Respectfully submitted,

DAVID A. JACKSON
Attorney for Applicant(s)
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
(201) 487-5800